Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia
Heinz Gisslinger(Medical University of Vienna), Róbert Královics(Medical University of Vienna), Guenther Nirnberger, Jelena D. Milosevic Feenstra(Austrian Academy of Sciences), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Ashot S. Harutyunyan(Yerevan State University), Martin Schalling(Karolinska University Hospital), Bettina Gisslinger(Medical University of Vienna), Tiina Berg(Austrian Academy of Sciences), Klaudia Bagienski(Austrian Academy of Sciences), Jüergen Thiele(University of Cologne), Leonhard Muellauer(Medical University of Vienna), Nicole C.C. Them(Austrian Academy of Sciences)
Cited by 1
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450